Hemogenyx Pharmplc Ls 01 Stock Current Valuation
| 5HU Stock | EUR 3.79 0.01 0.26% |
Valuation analysis of HEMOGENYX PHARMPLC helps investors to measure HEMOGENYX PHARMPLC's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that HEMOGENYX PHARMPLC's price fluctuation is out of control at this time. Calculation of the real value of HEMOGENYX PHARMPLC is based on 3 months time horizon. Increasing HEMOGENYX PHARMPLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the HEMOGENYX stock is determined by what a typical buyer is willing to pay for full or partial control of HEMOGENYX PHARMPLC LS 01. Since HEMOGENYX PHARMPLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HEMOGENYX Stock. However, HEMOGENYX PHARMPLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.79 | Real 2.89 | Hype 3.78 | Naive 4.47 |
The real value of HEMOGENYX Stock, also known as its intrinsic value, is the underlying worth of HEMOGENYX PHARMPLC Company, which is reflected in its stock price. It is based on HEMOGENYX PHARMPLC's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of HEMOGENYX PHARMPLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of HEMOGENYX PHARMPLC LS 01 helps investors to forecast how HEMOGENYX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HEMOGENYX PHARMPLC more accurately as focusing exclusively on HEMOGENYX PHARMPLC's fundamentals will not take into account other important factors: HEMOGENYX PHARMPLC LS 01 Company Current Valuation Analysis
HEMOGENYX PHARMPLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, HEMOGENYX PHARMPLC LS 01 has a Current Valuation of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 100.0% higher than that of the company.
HEMOGENYX Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HEMOGENYX PHARMPLC's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HEMOGENYX PHARMPLC could also be used in its relative valuation, which is a method of valuing HEMOGENYX PHARMPLC by comparing valuation metrics of similar companies.HEMOGENYX PHARMPLC is currently under evaluation in current valuation category among its peers.
HEMOGENYX Fundamentals
| Return On Equity | -0.32 | |||
| Return On Asset | -0.18 | |||
| Shares Outstanding | 979.75 M | |||
| Shares Owned By Insiders | 15.17 % | |||
| EBITDA | (2.62 M) | |||
| Net Income | (2.08 M) | |||
| Cash And Equivalents | 1.81 M | |||
| Total Debt | 1.63 M | |||
| Debt To Equity | 1.86 % | |||
| Current Ratio | 1.08 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.8 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 10 | |||
| Beta | 3.34 | |||
| Market Capitalization | 24.89 M | |||
| Z Score | 9.0 |
About HEMOGENYX PHARMPLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HEMOGENYX PHARMPLC LS 01's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HEMOGENYX PHARMPLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HEMOGENYX PHARMPLC LS 01 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HEMOGENYX Stock
HEMOGENYX PHARMPLC financial ratios help investors to determine whether HEMOGENYX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HEMOGENYX with respect to the benefits of owning HEMOGENYX PHARMPLC security.